William H. Rastetter, Director of Fate Therapeutics FATE, has filed 0 purchases and 7 sales on the open market. Over the past 12 months that comes to a net sale of $2.7M. The latest trade was on 06/12.

WR

WR

William H. Rastetter

Director

Company

Fate Therapeutics FATE

First filing

23/04/21

Trades

52 trades

Buys / sales

0 / 7

12-month net buying

−$2.7M

Last trade

06/12

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/11/05	25/11/06	18,000 sh	$151.82	$2,732,760	−30.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/05/05	25/05/07	30,000 sh	$110.20	$3,306,000	−44.5%
Neurocrine BiosciencesNBIX	Open-market sale	24/08/15	24/08/16	14,250 sh	$146.69	$2,090,332.5	−27.5%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/02	24/01/04	11,044 sh	$131.47	$1,451,954.68	−17.6%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/05/01	23/05/03	4,300 sh	$101.43	$436,149	−9.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/04/19–23/04/21	23/04/21	6,937 sh2 trades	$105.03avg.	$728,626.36	−15.0%